Sunshine Biopharma (NASDAQ:SBFM – Get Free Report) and Genocea Biosciences (NASDAQ:GNCA – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.
Earnings & Valuation
This table compares Sunshine Biopharma and Genocea Biosciences”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sunshine Biopharma | $36.31 million | 0.02 | -$5.97 million | ($12.90) | -0.09 |
| Genocea Biosciences | $1.91 million | 0.00 | -$33.20 million | ($0.61) | N/A |
Profitability
This table compares Sunshine Biopharma and Genocea Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sunshine Biopharma | -18.45% | -27.75% | -21.57% |
| Genocea Biosciences | N/A | -182.88% | -62.76% |
Insider & Institutional Ownership
42.0% of Sunshine Biopharma shares are held by institutional investors. Comparatively, 0.6% of Genocea Biosciences shares are held by institutional investors. 0.5% of Sunshine Biopharma shares are held by insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Risk and Volatility
Sunshine Biopharma has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings and target prices for Sunshine Biopharma and Genocea Biosciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sunshine Biopharma | 1 | 1 | 1 | 0 | 2.00 |
| Genocea Biosciences | 0 | 0 | 0 | 0 | 0.00 |
Sunshine Biopharma presently has a consensus price target of $70.00, suggesting a potential upside of 5,637.70%. Given Sunshine Biopharma’s stronger consensus rating and higher possible upside, analysts clearly believe Sunshine Biopharma is more favorable than Genocea Biosciences.
Summary
Sunshine Biopharma beats Genocea Biosciences on 8 of the 13 factors compared between the two stocks.
About Sunshine Biopharma
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.
About Genocea Biosciences
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.
Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
